Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Nanostring Technique Identifies Potential Melanoma Immunotherapy Targets

By BiotechDaily International staff writers
Posted on 23 Sep 2013
An advanced "nanostring" DNA expression analysis technique detected seven genes that are potential immunotherapy targets for the treatment of melanoma and could increase the number of patients potentially eligible for adoptive immunotherapy.

Nanostring technology is a variation of the DNA microarray that uses molecular "barcodes" and microscopic imaging to detect and count up to several hundred unique transcripts in one hybridization reaction. Each color-coded barcode is attached to a single target-specific probe corresponding to a gene of interest.

Investigators at the [US] National Cancer Institute (Bethesda, MD, USA) designed a nanostring probe set containing 97 genes, 72 of which were considered potential candidate genes for immunotherapy. Five established melanoma cell lines, 59 resected metastatic melanoma tumors, and 31 normal tissue samples were profiled and analyzed using the nanostring technique.

Results published in the September 10, 2013, online edition of the journal Clinical Cancer Research revealed that of the 72 potential target genes, 33 were overexpressed in more than 20% of studied melanoma tumor samples. Twenty of those genes were identified as differentially expressed between normal tissues and tumor samples. Analysis of normal tissue gene expression identified seven genes with limited normal tissue expression that warranted further consideration as potential immunotherapy target antigens: CSAG2, MAGEA3, MAGEC2, IL13RA2, PRAME, CSPG4, and SOX10. These genes were highly overexpressed on a large percentage of the studied tumor samples, with expression in a limited number of normal tissue samples at much lower levels.

“We identified seven potential candidate genes that deserve further consideration as targets for melanoma immunotherapy,” said senior author Dr. Richard Morgan, a researcher in the tumor immunology section of the [US] National Cancer Institute. “We used nanostring technology because it is very robust, yielding quantitative and extremely reproducible results and, in addition, an antigen expression profile can be constructed for a patient from a very small amount of tumor sample, which makes nanostring a better clinical tool.”

“Our laboratory has developed a battery of different antigen receptors to target a wide range of antigens, and we can engineer human immune cells to recognize the targets in patients’ tumors and kill those cells,” said Dr. Morgan. “This is a good example of how newer technologies like nanostring arm cancer researchers and clinicians with the best gear to make tremendous advancements in cancer research and treatment.”

Related Links:
[US] National Cancer Institute


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.